Vertex Pharma's most recent trend suggests a bullish bias. One trading opportunity on Vertex Pharma is a Bull Put Spread using a strike $115.00 short put and a strike $105.00 long put offers a potential 12.36% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $115.00 by expiration. The full premium credit of $1.10 would be kept by the premium seller. The risk of $8.90 would be incurred if the stock dropped below the $105.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Vertex Pharma is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Vertex Pharma is bullish.
The RSI indicator is at 79.26 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Vertex Pharma
What's in Store for Vertex (VRTX) this Earnings Season?
Mon, 24 Apr 2017 14:34:02 +0000
Vertex Pharmaceuticals, Inc. (VRTX) is scheduled to report first-quarter 2017 results on Apr 27, after the market closes.
3 Healthcare Bargain Stocks You Can Buy Right Now
Mon, 24 Apr 2017 13:42:00 +0000
Allergan, Express Scripts, and Vertex stocks look attractive in a generally overpriced market.
3 Stocks That Growth Investors Should Love
Sun, 23 Apr 2017 15:01:00 +0000
Impressive growth could be in store for biotech stocks Celgene, Ionis, and Vertex.
Trump invites Vertex CEO to White House for biotech summit
Fri, 21 Apr 2017 20:45:07 +0000
Vertex Pharmaceuticals CEO Jeffrey Leiden is among a group of pharmaceutical executives that have reportedly been invited to meet with top officials from the Trump Administration next month to discuss issues facing the industry — a sign of the Boston drugmaker’s growing clout. The planned May 8 meeting at the White House was reported by Bloomberg News on Friday afternoon . A spokesperson for Vertex (VRTX), one of the largest drug companies based in Massachusetts, confirmed that Leiden has been invited to the summit, but declined to say whether he will attend.
Vertex at odds with religious investors over lobbying disclosures
Tue, 18 Apr 2017 23:44:14 +0000
Two religious organizations that own shares of Vertex Pharmaceuticals are pushing the Boston drugmaker to disclose more information about its lobbying on drug pricing and other hot-button issues, an effort that the company opposes. Vertex (VRTX) said in a federal filing Monday that it will ask shareholders to reject the measure during its annual meeting in June. The measure would require Vertex to disclose how much it spends on lobbying at the local, state and federal levels, including payments it makes to trade groups and spending on “grassroots” communications that seek to shape public opinion on policy issues.
Also on Market Tamer…
Follow Us on Facebook